DNAJC5 and malaria: Intriguingly, a recent analysis of pooled HLA-A, -B, and -DRB1 data from six randomized trials of RTS,S, the leading malaria vaccine candidate, found that HLA-B*53 was associated with a lack of protection in vaccine recipients, as well as lower post-vaccination titers of anti-CSP antibodies (33).